Zhongshan Lebo Ruichen Biopharmaceutical

Lebo Ruichen Biopharmaceutical is a biotechnology company based in Zhongshan, China, dedicated to the innovation of mRNA-based therapeutics and vaccines. The company utilizes its proprietary lipid nanoparticle (LNP) delivery technology and mRNA sequence optimization platform to develop treatments for infectious diseases and oncology. Their pipeline features mRNA vaccine candidates for COVID-19 and shingles, which are progressing through pre-clinical and IND-enabling phases. Lebo Ruichen is focused on building a vertically integrated mRNA drug development capability, including discovery, clinical development, and large-scale GMP manufacturing. The company is a significant contributor to the biopharmaceutical innovation ecosystem in the Guangdong-Hong Kong-Macao Greater Bay Area.